Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EpiPen Medicaid Rebates Could Increase As Mylan, CMS Dispute Heats Up

Executive Summary

Mylan, agency take opposing views on whether the company has been overcharging Medicaid for EpiPen, which is currently classified as a generic for the purposes of program rebates.

You may also be interested in...



Medicaid Discount Classification: Will Trump And Grassley Tag Team Against Pharma?

Confirmation hearing for HHS Nominee Price could give Sen. Grassley chance to get new administration on record prioritizing enforcement against drugs that have been providing smaller than appropriate Medicaid discounts.

Medicaid Rebates Will Get Broad OIG Review After EpiPen

HHS Inspector General tells congressional committee chairmen it will investigate whether other drugs may be improperly classified as generics in Medicaid to avoid higher rebate requirements.

Investors Relieved As Mylan Settlement Avoids Investigation

Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel